Your first 90 days
Your first 90 days on Amvuttra for ATTR amyloidosis with cardiomyopathy
What happens before the first fill, the days that matter, the label's rules and who to call, from the label, the drugmaker's own program and one insurer's written rules.
Amvuttra is not a pill and not a pharmacy pickup. It is a single injection that a nurse or doctor gives every 3 months. That makes the first 90 days quieter than most, with dose 1 at the start, a daily vitamin A supplement in between and dose 2 at the far end. This page lays out that stretch from the FDA label, Alnylam's own support program and one insurer's written rules.
What has to happen before the first bottle ships
Amvuttra has no REMS, but it is a specialty drug given in a clinic or at home. The first dose waits on a Start Form, an insurance approval and a place to give it. These are the 5 things in the way, in order.
A Start Form signed by you and your cardiologist
The Alnylam Assist Start Form enrolls you in Alnylam's support program and carries the prescription itself.
- It is written for one prefilled syringe of 25mg every 3 months.
- Your signature is required, and the office faxes it or submits it online.Start Form
A call from an Alnylam Case Manager
Within 2 business days of the Start Form, a Case Manager contacts you and your doctor with a summary of your insurance benefits.
- The same person keeps you updated on the prior authorization and any appeal.Alnylam Assist
The insurance approval
Most plans require prior authorization, and the usual criteria are further down this page.
- If a new patient's request is denied, or is still pending on the seventh calendar day, the office can ask for one free dose.
- That is the Alnylam Assist Quick Start Program.Quick Start form
Choosing where the shot is given
Alnylam says you and your doctor can choose the doctor's office, a treatment center, or your home, depending on your insurance.
- After the Start Form, Alnylam Assist can send a list of treatment sites that fit your coverage and preferences.Alnylam Assist
A plan for vitamin A
The label advises a vitamin A supplement at the recommended daily allowance for everyone on Amvuttra.
- It warns against taking more to push the blood level back to normal.
- Ask your cardiologist which product to use and when to begin.FDA label
The days that matter
Counted from the first injection, with the vitamin A start, the check-in before the next visit and dose 2 about 3 months later. Days before the first dose are estimates, because paperwork and insurance set the pace. Type your first-dose date and the tiles become real dates you can add to your calendar.
The tiles below count days from a first dose. Enter the date of yours, or the date you expect, and each tile becomes a real date on your calendar.
The date stays on your device. It is not sent to Trial Friend or anyone else. The calendar file works with Apple, Google and Outlook calendars.Start Form signed and sent
You and your cardiologist sign the Start Form, which also carries the prescription.
- The office faxes it to Alnylam Assist or submits it online.
A Case Manager calls
An Alnylam Case Manager contacts you and your doctor with a summary of your benefits.
- The program says the call is where its support begins.
Prior authorization, and the 7-day mark
The office sends the insurer the diagnosis records it asks for.
- A new patient whose request is denied, or still pending on the seventh day, may get one dose free through Quick Start.
Where the shot is given
The doctor's office, a treatment center, or your home if your insurance covers it.
- The Case Manager can send a list of sites that fit your plan.
Dose 1, one 25mg injection
A healthcare professional injects one prefilled syringe under the skin of the belly, thigh or upper arm.
- Alnylam's guide for clinicians says no premedication is needed and the label sets no waiting period afterward.
Daily vitamin A, at the recommended amount
The label advises a daily supplement at the recommended daily allowance for everyone taking Amvuttra.
- It names no start day, so your cardiologist says when to begin.
The injection site
In the nerve trial, 4% of patients had a reaction where the shot went in, such as bruising, redness, pain, itching or warmth.
- The label says these were mild and passed.
Reminder and check-in
Alnylam Case Managers schedule check-ins before and after each treatment and send reminders.
- It is a good week to confirm the appointment and that your approval still holds.
Dose 2, then every 3 months
The label's schedule is one injection every 3 months.
- Each carton holds a single syringe, so every visit uses a new one.
- A late dose is given as soon as possible, and the 3-month clock restarts from that date.
Dose 2, number 2
The label, revision by revision
The FDA lists which sections changed in each revision of a label. These are the revisions the current Amvuttra label records, dated by the FDA, with a plain note on what each one meant for a patient. Older references and handouts can lag these by months.
Current label dated November 6, 2025, read from the FDA's label database today. FDA label
- November 2025
DailyMed carries a new version of the label dated November 6th. Its text still reads Revised 3/2025, and the FDA's approval letters stop at March 2025, so the changes below are the approved ones.FDA label
- March 2025
Results of a 2-year cancer study in mice were added on March 11th. The label reports no increase in tumors.FDA letter
- February 2023
Updated safety data from the HELIOS-A nerve trial and a 2-year cancer study in rats were added to the label.FDA letter
- June 2022
First approval, on June 13th, for the nerve damage of hereditary ATTR amyloidosis in adults. That use continues alongside the heart use and is not the subject of this page.FDA letter
How the label says to take it
The parts of the prescribing information and the patient leaflet that come up in the first 3 months, in plain words.
- Given by a healthcare professional, not at home by yourself
The label says Amvuttra is for use under the skin only and should be given by a healthcare professional.
- Alnylam says it can be given at the doctor's office, a treatment center or even at home, depending on your insurance.Taking Amvuttra
- If a dose is missed
The label says to give the missed dose as soon as possible.
- Dosing then resumes every 3 months from that most recent injection, not from the original date.FDA label
- Vitamin A every day, at the recommended amount and no more
Amvuttra lowers vitamin A in the blood.
- In the heart trial, 80% of patients with a normal level at the start developed a low level.
- The label says to supplement at the recommended daily allowance and not to take more to chase a normal blood level.
- The blood level does not reflect the body's total store.FDA label
- Your eyes
Low vitamin A can affect vision.
- The label says patients with eye symptoms that suggest vitamin A deficiency, such as night blindness, should be referred to an eye specialist.
- Alnylam's patient site says to tell your doctor about any vision problem.Taking Amvuttra
- Other medicines
The label lists no contraindications and no drug interactions.
- It says no clinical interaction studies were done, and lab studies suggest vutrisiran does not act on the liver enzymes behind most drug interactions.
- Tell the cardiologist about every multivitamin, because it may already contain vitamin A.FDA label
- Tafamidis and Attruby
The label does not bar taking Amvuttra with a stabilizer.
- In the HELIOS-B trial, 40% of patients were on tafamidis at the start.
- Some insurers will not pay for both at once, and the cardiologist decides what you take.FDA label
- Pregnancy and breastfeeding
The label says to tell your healthcare provider if you are pregnant or plan to be.
- Vitamin A matters for a baby's development, but too much can harm it, and the effects of Amvuttra on a pregnancy are unknown.
- Whether it passes into breast milk is also unknown.FDA label
- Storage, for home doses
Between 36 and 86 degrees Fahrenheit (2 to 30 Celsius), in the original carton, never frozen.
- A cold syringe sits at room temperature for 30 minutes before the injection.FDA label
What the label says to act on
The symptoms the label singles out, and what it tells patients and prescribers to do about each. If any of these happen, the label's instruction is the one to follow, with your care team.
Night blindness or other vision changes
The label ties trouble seeing in dim light to low vitamin A and says these patients should see an eye specialist.
- Alnylam's patient site says to talk to your doctor about any vision problem while on Amvuttra.Taking Amvuttra
The most common side effects
In the HELIOS-A nerve trial, 15% of patients had pain in the arms or legs and 11% had joint pain.
- Shortness of breath and low vitamin A each occurred in 7%.
- The label says the HELIOS-B heart trial found no new safety issues.FDA label
A reaction where the shot went in
Bruising, redness, pain, itching or warmth at the injection site occurred in 4% of patients in the nerve trial.
- The label describes them as mild and short-lived, so one that lingers is worth mentioning at the next visit.FDA label
Why the pharmacy or the insurer says no, and what fixes it
Most first-fill delays are one of these. Knowing which one tells you who to call.
- Prior authorization pending or deniedA new patient whose request is denied, or still pending 7 calendar days after it was sent, may get one dose free through the Alnylam Assist Quick Start Program. The office needs a Start Form on file first, and a licensed provider signs the request.Quick Start form
- The plan wants more recordsPlans such as Cigna ask for how the diagnosis was confirmed, heart imaging that shows involvement, and the symptom class. The cardiologist's records usually settle it, and the Case Manager keeps you updated on the appeal.Cigna policy
- The plan will not pay alongside tafamidis or AttrubyCigna's policy treats Amvuttra given with tafamidis, Attruby or another ATTR drug as not medically necessary. The label does not bar the combination. The cardiologist's office decides whether to appeal or change the plan of treatment.Cigna policy
- The place of the injection is not coveredA home dose depends on insurance, and some plans limit where a dose can be given. The Case Manager can send a list of treatment sites that your coverage accepts.Alnylam Assist
- Your insurance changed partway throughThe Alnylam Assist Bridge Program supplies medicine to eligible patients whose coverage changes and delays a dose. A Case Manager checks eligibility once a Start Form is on file.Alnylam Assist HCP
- A cost you cannot payCommercial insurance: the Alnylam Assist Copay Program, which covers certain out-of-pocket costs. People on Medicare, Medicaid or other government plans cannot use it. Alnylam says most Medicare patients have coverage, and its Patient Assistance Program gives the drug free to eligible people, mainly the uninsured.Amvuttra financial support
Cigna prior authorization policy, April 15, 2026
- Age 18 or older, with ATTR cardiomyopathy, wild-type or hereditary
- Diagnosis confirmed by a technetium pyrophosphate heart scan, a tissue biopsy typed as TTR amyloid, or a genetic test showing a disease-causing TTR variant
- Heart imaging, such as an echocardiogram or cardiac MRI, showing the heart is involved
- Heart failure, but not New York Heart Association (NYHA) class IV
- Prescribed by or with a cardiologist or an amyloidosis specialist
- A dose of 25mg, no more often than once every 3 months
- Not combined with tafamidis, Attruby, Onpattro, Tegsedi or Wainua
Approval length. A year at a time. The policy lists no separate renewal criteria for the heart use.
This policy was reviewed in March 2026, after the March 2025 label added the heart use. Its ban on combining with tafamidis or Attruby is the plan's rule, not the label's, and 40% of patients in the HELIOS-B trial were already on tafamidis. The federal employee Blue Cross policy from April 2026 asks for other things. Those include an NT-proBNP of 600 or more, a heart failure history, and a genetic test or biopsy. It is here as an example of what a plan asks for, not as a rule. Cigna policy
Who to call, and what they can do
The drugmaker's program handles most of the first-fill problems above. Charity funds and foundation help are on the help paying page.
- Alnylam Case Managers who verify your insurance coverage, check whether you qualify for financial help and work to keep you on Amvuttra, once your doctor sends a Start Form
- The Alnylam Assist Copay Program, which covers certain out-of-pocket costs for eligible people with commercial insurance, not for Medicare, Medicaid or other government plans
- Programs that may help during a delay or gap in coverage, with eligibility set by a Case Manager
- The Alnylam Assist Patient Assistance Program, which may give Amvuttra at no cost to eligible people, mainly the uninsured
- Patient Education Liaisons, Alnylam employees who help you understand the disease and answer questions about Amvuttra but are not part of your care team
Details as the drugmaker publishes them. Amvuttra financial support
Five questions for the pharmacist or the support line
- Will my dose be given at the office, a treatment center or at home, and does my plan cover that place?
- Which vitamin A supplement and amount should I take, and does my multivitamin already count toward it?
- Is my plan paying for Amvuttra under my medical benefit or my pharmacy benefit, and what will I owe each dose?
- Is dose 2 already on the calendar, and who calls me if it needs to move?
- I take tafamidis now. Does my plan allow both, and what has my cardiologist decided?
Questions people ask in the first weeks
How is Amvuttra given?
As one 25mg injection under the skin every 3 months, by a healthcare professional. The label says it is not for self-injection, and Alnylam says it can be given at a doctor's office, a treatment center or at home, depending on insurance.
Do I need a vitamin A supplement on Amvuttra?
Yes, the label advises a daily supplement at the recommended daily allowance. It also says not to take more than that to raise the blood level, because the blood level does not reflect the body's total vitamin A. Your cardiologist names the product and the start date.
What eye symptoms should I watch for on Amvuttra?
Trouble seeing at night or in dim light, which the label links to low vitamin A. The label says these patients should be referred to an eye specialist, and Alnylam's patient site says to tell your doctor about any vision problem.
What if I miss a dose of Amvuttra?
The label says the missed dose is given as soon as possible. The next one then falls 3 months after that late dose, not on the original schedule.
Can I take Amvuttra with tafamidis or Attruby?
The label does not bar it, and 40% of patients in the HELIOS-B heart trial were on tafamidis at the start. Cigna's policy, one example, will not pay for Amvuttra alongside tafamidis or Attruby. The cardiologist decides what you take, and the office can appeal.
Does Amvuttra need blood tests or a REMS?
No REMS, and the label requires no blood test before a dose. Alnylam's guide for clinicians says lab monitoring and premedication are not required. Your cardiologist will still follow your heart condition in the usual way.
Why was Amvuttra denied by my insurance?
Plans such as Cigna ask for proof of how the diagnosis was confirmed, imaging that shows heart involvement, and the symptom class. Some plans also refuse to pay alongside tafamidis or Attruby. The Case Manager can track the appeal, and a new patient may get one dose free through Quick Start while it is sorted out.
Free email alert
Hear when the Amvuttra label changes
One email the day the FDA revises the Amvuttra label, with what changed in plain words. No trial alerts, no newsletter.
Label changes for Amvuttra only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Want the whole condition instead? Follow ATTR amyloidosis with cardiomyopathy for new trials, FDA decisions and label changes for every treatment.
Sources
- AMVUTTRA (vutrisiran) injection, for subcutaneous use, Revised: 3/2025, Alnylam Pharmaceuticals, via DailyMed, November 6, 2025.
- AMVUTTRA® (vutrisiran) Dosing and Administration Guide (AMV-USA-00071-V3), Alnylam Pharmaceuticals, November 7, 2026.
- Taking AMVUTTRA | AMVUTTRA® (vutrisiran), Alnylam Pharmaceuticals, November 7, 2026.
- Coverage & Starting Treatment | AMVUTTRA® (vutrisiran) | Alnylam Assist®, Alnylam Pharmaceuticals, November 7, 2026.
- Support & Education Teams | AMVUTTRA® (vutrisiran) | Alnylam Assist®, Alnylam Pharmaceuticals, November 7, 2026.
- Support & Education Teams | AMVUTTRA® (vutrisiran) | Alnylam Assist® HCP, Alnylam Pharmaceuticals, November 7, 2026.
- Financial Assistance & Support | AMVUTTRA® (vutrisiran), Alnylam Pharmaceuticals, November 7, 2026.
- Financial Assistance | AMVUTTRA® (vutrisiran) | Alnylam Assist® HCP, Alnylam Pharmaceuticals, November 7, 2026.
- Alnylam Assist® Copay Program Enrollment, Terms and Conditions, Alnylam Pharmaceuticals, November 7, 2026.
- Alnylam Assist® Start Form, AMVUTTRA® (vutrisiran) (AMV-USA-00015-V6), Alnylam Pharmaceuticals, November 7, 2026.
- Alnylam Assist® Quick Start Program enrollment form (AMV-USA-01095-V3), Alnylam Pharmaceuticals, November 7, 2026.
- AMVUTTRA® (vutrisiran) Product Characteristics (AMV-USA-00034-V4), Alnylam Pharmaceuticals, November 7, 2026.
- Drug Coverage Policy IP0478, Amyloidosis – Amvuttra, Cigna, April 15, 2026.
- 5.75.037, Prescription Drugs, Amvuttra, Blue Cross Blue Shield Federal Employee Program, April 1, 2026.
- NDA 215515/S-006 supplement approval letter, cardiomyopathy indication, FDA, March 20, 2025.
- NDA 215515/S-005 supplement approval letter, section 13.1 mouse carcinogenicity, FDA, March 11, 2025.
- NDA 215515/S-002 supplement approval letter, sections 6.1 and 13.1, FDA, February 16, 2023.
- NDA 215515 approval letter, FDA, June 13, 2022.
This page explains what the FDA label, the drugmaker's support program and an insurer policy say. It is not medical advice and does not tell anyone to start, stop or change a medicine. Dosing, test timing and restarts after a gap are decisions for the prescribing cardiologist. Found an error? Use the report link in the footer and it will be checked against the source.